Growth Opportunities F. Forbion Purchases 41,639 Shares of enGene Holdings Inc. (NASDAQ:ENGN) Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion purchased 41,639 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $5.97 per share, for a total transaction of $248,584.83. Following the completion of the transaction, the insider now owns 2,059,459 shares of the company’s stock, valued at $12,294,970.23. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

enGene Stock Performance

Shares of NASDAQ:ENGN opened at $9.02 on Friday. enGene Holdings Inc. has a 1 year low of $4.42 and a 1 year high of $43.00. The stock has a market capitalization of $398.38 million, a price-to-earnings ratio of -5.24 and a beta of -0.69. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The company’s 50 day simple moving average is $6.71 and its 200 day simple moving average is $9.73.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, research analysts predict that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Altitude Crest Partners Inc. bought a new stake in shares of enGene during the 1st quarter valued at approximately $2,039,000. SR One Capital Management LP acquired a new stake in enGene in the second quarter valued at approximately $4,715,000. Logos Global Management LP grew its stake in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of enGene during the first quarter worth $17,095,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.